-
公开(公告)号：US20220195044A1
公开(公告)日：2022-06-23
申请号：US17693323
申请日：2022-03-12
Applicant: Immatics Biotechnologies GmbH
Inventor： Martin HOFMANN , Felix UNVERDORBEN , Sebastian BUNK , Dominik MAURER
Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.
-
公开(公告)号：US20210388079A1
公开(公告)日：2021-12-16
申请号：US17397656
申请日：2021-08-09
Applicant: Immatics Biotechnologies GmbH
Inventor： Claudia WAGNER , Leonie ALTEN , Sebastian BUNK , Dominik MAURER
IPC: C07K16/26 , C07K14/725 , C07K14/81 , C07K16/28 , C07K16/38 , C12N15/85 , C12N5/0783
Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular the TAA Serine protease inhibitor Kazal-type 2 (SPINK2). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and SPINK2 binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of SPINK2 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
-
公开(公告)号：US20200263162A1
公开(公告)日：2020-08-20
申请号：US16869784
申请日：2020-05-08
Applicant: Immatics Biotechnologies GmbH
Inventor： Sebastian BUNK , Dominik MAURER , Felix UNVERDORBEN
Abstract: The present invention relates to improved yeast transformation of yeast cells and yeast cell libraries transformed thereby. More specifically, the present invention relates to the transformation of yeast by electroporation.
-
公开(公告)号：US20190284276A1
公开(公告)日：2019-09-19
申请号：US16402829
申请日：2019-05-03
Applicant: Immatics Biotechnologies GmbH
Inventor： Leonie ALTEN , Dominik MAURER , Steffen WALTER , Sebastian BUNK
Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
-
公开(公告)号：US20190269769A1
公开(公告)日：2019-09-05
申请号：US16413939
申请日：2019-05-16
Applicant: Immatics Biotechnologies GmbH
Inventor： Dominik MAURER , Leonie ALTEN , Sebastian BUNK
IPC: A61K39/00 , C07K14/725 , G01N33/574 , A61K45/06 , C07K14/74
Abstract: The present description relates to T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. In particular, the present description relates to TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as IGF2BP3-001 have the amino acid sequence of KIQEILTQV (SEQ ID NO:1). The present description further relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer. The present description furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
Patent Agency Ranking
公开(公告)号：US20190135914A1
公开(公告)日：2019-05-09
申请号：US16180980
申请日：2018-11-05
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Felix UNVERDORBEN , Sebastian BUNK , Martin HOFMANN , Dominik MAURER , Meike HUTT , Claudia WAGNER , Leonie ALTEN
IPC: C07K16/28 , C12N15/62 , C12N5/0783 , A61P35/00 , C07K14/775
Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
-
公开(公告)号：US20190016804A1
公开(公告)日：2019-01-17
申请号：US16035429
申请日：2018-07-13
Applicant: Immatics Biotechnologies GmbH
Inventor： Martin HOFMANN , Felix UNVERDORBEN , Sebastian BUNK , Dominik MAURER
Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated viral peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.
-
公开(公告)号：US20190002556A1
公开(公告)日：2019-01-03
申请号：US16023731
申请日：2018-06-29
Applicant: Immatics Biotechnologies GmbH
Inventor： Claudia WAGNER , Leonie ALTEN , Sebastian BUNK , Dominik MAURER
IPC: C07K16/26 , C12N5/0783 , C12N15/85
Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular the TAA Serine protease inhibitor Kazal-type 2 (SPINK2). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and SPINK2 binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of SPINK2 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
-
公开(公告)号：US20180319884A1
公开(公告)日：2018-11-08
申请号：US16035300
申请日：2018-07-13
Applicant: Immatics Biotechnologies GmbH
Inventor： Leonie ALTEN , Dominik MAURER , Steffen WALTER , Sebastian BUNK
Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
-
公开(公告)号：US20250122302A1
公开(公告)日：2025-04-17
申请号：US18989486
申请日：2024-12-20
Applicant: Immatics Biotechnologies GmbH
Inventor： Sara YOUSEF , Fabian BRUNK , Andreas MORITZ , Sebastian BUNK , Claudia WAGNER , Dominik MAURER , Felix UNVERDORBEN
IPC: C07K16/30 , C07K14/725 , G01N33/574
Abstract: The present invention provides an antigen binding protein specifically binding to a CT45 antigenic peptide that is in a complex with a major histocompatibility complex (MHC) protein, wherein the CT45 antigenic peptide comprises or consists of the amino acid sequence of SEQ ID NO: 138 (KIFEMLEGV) and wherein the antigen binding protein comprises a first polypeptide comprising a variable domain VA comprising complementarity determining regions CDRa1, CDRa2 and CDRa3 and a second polypeptide comprising a variable domain VB comprising CDRb1, CDRb2 and CDRb3. Also provided are nucleic acids encoding the antigen binding proteins, vectors comprising the nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins. The invention further provides the antigen binding proteins for use in medicine and a method of producing the antigen binding protein.
-
-
-
-
-
-
-
-
-
Search Results
57
records
(took 0.025 seconds)
